Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.

Cardiovasc Diabetol · 2020 · PMC7271387 · PMID 32493344

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

a trend level of significancep = 0.06so close (0.05 < p ≤ 0.1)

6 a), At Visit 1, the linagliptin group demonstrated lower PWV at a trend level of significance (p = 0.06).

also in 82 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.